Voyager Therapeutics Names Alfred Sandrock as CEO, Former Biogen R&D Head Sandrock spent 23 years at Biogen, where he was head of R&D and chief medical officer. 2 MIN READ 03.24.2022
Voyager Therapeutics Signs Deal with Neurocrine for Parkinson’s Disease and Friedreich’s Ataxia Voyager gets $165 million upfront + up to $1.7 billion in potential milestone payments 4 MIN READ 01.30.2019
Voyager Therapeutics Signs Alzheimer’s Gene Therapy Deal with AbbVie Worth up to $1.1 Billion $69 million upfront + up to $155 million in preclinical and Phase 1 options + up to $895 million in developmental milestones. 3 MIN READ 02.20.2018
Voyager Therapeutics (VYGR): Gene Therapy for Severe Neurological Diseases Voyager Therapeutics is developing targeted gene therapies for severe neurological diseases. 4 MIN READ 07.20.2017
